Basic Components and Characteristics of Tumours

A tumour is an ecosystem, not just a lump of malignant cells. Its neoplastic parenchyma grows within a supporting stroma of vessels, fibroblasts, extracellular matrix and immune cells. The interaction between these components determines growth, necrosis, invasion, treatment response and clinical presentation. Understanding the components and characteristics of tumours helps the clinician interpret a mass, communicate with pathology and recognise urgent complications.

Learning outcomes

The learner should be able to identify the parenchymal and stromal components of a tumour, explain the tumour microenvironment, describe the major biological hallmarks of cancer, correlate microscopic and macroscopic features with clinical behaviour, and recognise features that require urgent evaluation.

1. Parenchyma: the neoplastic cell population

The parenchyma consists of transformed cells derived from a founding clone. It determines the tumour’s lineage and is assessed by morphology, immunohistochemistry, flow cytometry and molecular studies. Tumour cells may be uniform or heterogeneous because additional alterations create subclones over time.

1.1 Differentiation

Well-differentiated cells resemble their tissue of origin and may retain specialised functions such as mucus, keratin, hormones or melanin production. Poorly differentiated or anaplastic cells show little resemblance to normal tissue and often behave more aggressively, although grade and prognosis are organ-specific.

1.2 Clonality and heterogeneity

Many tumours begin from one altered cell, but the clone evolves. Regions of the same tumour may differ in mutations, grade, oxygenation and immune infiltration. Sampling error can therefore miss a clinically important subclone; pathology integrates the specimen with imaging and clinical findings.

2. Stroma: the tumour’s supporting framework

Stromal component	Role	Clinical effect
Blood vessels/endothelial cells	Deliver oxygen and nutrients; remove waste	Support growth, bleeding and haematogenous spread
Lymphatics	Drain interstitial fluid and provide a route to nodes	Enable regional metastasis
Fibroblasts	Produce extracellular matrix and growth factors	Desmoplasia, firmness and altered drug penetration
Extracellular matrix	Provides structure and biochemical signals	Controls invasion, migration and tissue stiffness
Macrophages and other immune cells	Can attack tumour or promote growth and repair-like responses	Immune surveillance, inflammation and immune escape
Pericytes and smooth muscle cells	Stabilise vessels and regulate permeability	Abnormal vessels may leak, thrombose or support invasion

3. Tumour microenvironment

Tumour cells release cytokines, chemokines, growth factors and extracellular vesicles that recruit and reprogramme stromal cells. Fibroblasts may become cancer-associated fibroblasts; macrophages may acquire tumour-supporting functions; endothelial cells form abnormal vessels. Low oxygen selects cells able to survive hypoxia and stimulates angiogenic signals. The microenvironment can also suppress T-cell activity and reduce drug delivery.

4. Major characteristics and hallmarks

4.1 Sustaining proliferative signalling

Normal cells require regulated growth signals. Tumour cells may produce their own signals, amplify receptors or activate downstream pathways such as RAS–MAPK and PI3K–AKT. The result is persistent division despite absent normal stimuli.

4.2 Evading growth suppressors

Normal tissues use checkpoints and tumour-suppressor proteins to limit proliferation. Loss of pathways involving RB, p53, TGF-beta or contact inhibition allows cells with damage or crowding to continue dividing.

4.3 Resisting cell death

Apoptosis removes dangerous or damaged cells. Tumours may lose pro-apoptotic signals, increase anti-apoptotic proteins, avoid immune killing or adapt to hypoxia. Necrosis and autophagy can also influence survival and inflammation.

4.4 Enabling replicative immortality

Most somatic cells have limited division because telomeres shorten. Many cancers reactivate telomerase or alternative lengthening mechanisms, allowing repeated replication.

4.5 Inducing or co-opting angiogenesis

A growing mass requires new or recruited vessels. Hypoxia-inducible factors and vascular endothelial growth factor stimulate angiogenesis. Tumour vessels are irregular, fragile and leaky, causing haemorrhage, oedema, hypoxia and variable drug delivery.

4.6 Activating invasion and metastasis

Malignant cells reduce adhesion, degrade basement membranes, migrate through stroma, enter vessels, survive circulation and colonise distant organs. Organ tropism depends on blood flow, adhesion molecules, chemokines and the “seed-and-soil” relationship between tumour cells and target tissue.

4.7 Avoiding immune destruction

Tumours can reduce antigen presentation, express inhibitory ligands, recruit regulatory immune cells and create an immunosuppressive microenvironment. Immune surveillance still eliminates many abnormal cells, but successful clones evolve ways to escape.

4.8 Deregulating cellular metabolism

Many tumours favour aerobic glycolysis and increase glucose uptake even when oxygen is available (the Warburg effect). Metabolic rewiring supports rapid biosynthesis and survival in a changing microenvironment, but it also creates imaging and therapeutic vulnerabilities.

4.9 Maintaining genome instability

Defects in DNA repair, chromosome segregation or cell-cycle checkpoints increase mutation and structural variation. Genome instability accelerates evolution of resistant subclones and may create targets for therapy.

4.10 Tumour-promoting inflammation

Chronic inflammatory cells and mediators can stimulate proliferation, angiogenesis, tissue remodelling and immune suppression. Infection, smoking, reflux, inflammatory bowel disease and other chronic injuries may create a cancer-promoting environment in susceptible tissues.

5. Macroscopic characteristics

Gross feature	Possible meaning	Clinical correlation
Well circumscribed/encapsulated	Expansile growth and compression	Often benign, but not proof of benignity
Infiltrative irregular edge	Extension through normal tissue	Suggests malignancy and incomplete excision risk
Firm, white, fibrous cut surface	Desmoplastic stroma	Hard palpable lesion; common in some carcinomas
Soft, friable, haemorrhagic	Rapid growth, fragile vessels or necrosis	Bleeding, anaemia and urgent deterioration
Central necrosis/cavitation	Growth outstrips blood supply	Fever, pain, foul discharge or fistula may occur
Ulceration	Tumour breaks through surface epithelium	Bleeding, infection, pain and difficulty healing
Satellite nodules or nodes	Local lymphatic or discontinuous spread	Staging and biopsy of appropriate site

6. Microscopic characteristics

• Pleomorphism and variation in cell and nuclear size.
• Hyperchromatic enlarged nuclei and a high nuclear-to-cytoplasmic ratio.
• Loss of polarity and architectural disorganisation.
• Abnormal mitotic figures and increased proliferation index.
• Necrosis, apoptotic debris and inflammatory infiltrates.
• Invasion through basement membrane, nerves, vessels or adjacent organs.
• Specialised products such as keratin pearls, mucin, hormones or pigment may identify differentiation.

These findings are interpreted within organ-specific criteria. Atypia can occur in reactive conditions, and not every high mitotic rate means malignancy.

7. Tumour growth patterns

Expansile growth

A mass grows by pushing against adjacent tissue and may form a capsule or pseudocapsule. Compression can cause atrophy, obstruction or pain. Surgical planes may be clearer, but a capsule does not guarantee complete microscopic clearance.

Infiltrative growth

Cells dissect through stroma, nerves, vessels and organs. The gross lesion may be smaller than the true microscopic extent, so margins and imaging are important.

Exophytic, papillary, polypoid and ulcerative patterns

Surface tumours may project into a lumen or outward. Papillary and polypoid lesions can bleed or obstruct; ulcerated lesions are vulnerable to infection and repeated trauma.

Diffuse and infiltrative patterns

Some tumours thicken an organ wall or spread through marrow, meninges or serosal surfaces without forming a discrete mass. A normal-looking surface does not exclude extensive disease.

8. Tumour-associated necrosis and inflammation

Rapid growth can exceed blood supply and cause ischaemic necrosis. Necrotic tumour may produce fever, leukocytosis, pain and foul discharge, mimicking infection. Infection may coexist, especially in an ulcerated or obstructing lesion. Evaluate sepsis, obtain cultures when appropriate and do not assume every fever is paraneoplastic.

9. Clinical effects of tumour components

• Mass effect: obstruction of airway, bowel, bile duct, ureter or cerebrospinal-fluid pathways.
• Vascular/lymphatic effects: thrombosis, oedema, superior vena cava syndrome or lymphoedema.
• Nerve involvement: pain, neuropathy, weakness or autonomic dysfunction.
• Surface effects: ulceration, bleeding, infection and malodour.
• Endocrine effects: hormone excess or ectopic hormone production.
• Systemic effects: cachexia, anaemia, fever, thrombosis and metabolic derangements.

10. Tumour heterogeneity and treatment resistance

A tumour contains subclones with different mutations and microenvironments. Treatment may eliminate sensitive cells while selecting resistant populations. Hypoxic regions may be less sensitive to radiotherapy; poor perfusion may limit drug delivery; and immune-excluded areas may evade immunotherapy. This is why molecular testing, repeat biopsy or re-staging may be needed when a tumour changes behaviour.

11. Specimen handling and pathology communication

1. Record the site, side, lesion size, imaging impression and clinical differential.
2. Send tissue in the correct container and medium; use fresh or special handling when lymphoma, microbiology or molecular testing is suspected.
3. Do not place every specimen in formalin without checking the test required.
4. Orient and label margins when excision is performed.
5. Include previous cancer, treatment, immunosuppression and relevant family history.
6. Correlate biopsy, imaging and clinical findings; discordance should trigger review rather than forced certainty.

12. Emergency presentations

13. Benign tumours can still be emergencies

Benign intracranial tumours can raise intracranial pressure; a pituitary adenoma can cause visual loss or adrenal crisis; a benign airway lesion can obstruct ventilation; and a vascular tumour can bleed. Behaviour, location and function matter more than the word “benign” alone.

14. Practical comparison: reactive lesion versus neoplasm

Feature	Reactive/adaptive proliferation	Neoplastic proliferation
Trigger	Identifiable injury, infection, hormone or demand	Genetic/epigenetic clone with relative autonomy
Growth control	Usually stops when stimulus resolves	Persists after trigger removal
Architecture	Often preserves normal maturation and polarity	May show atypia, disorganisation and abnormal differentiation
Invasion	Absent	Possible in malignancy
Clinical plan	Treat cause and reassess	Pathology, staging and multidisciplinary management

References and further reading

• NCI: What is cancer?.
• NCI Dictionary: Tumour definition.
• WHO: Cancer overview.
• NCI: Tumour grade and staging.
• Follow local pathology specimen, oncology, emergency and referral protocols.